Iron Metabolism Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major iron metabolism disorders markets are expected to exhibit a CAGR of 3.55% during 2024-2034.
The iron metabolism disorders market has been comprehensively analyzed in IMARC's new report titled "Iron Metabolism Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Iron metabolism disorders encompass a group of medical diseases characterized by abnormal levels of iron in the body. The symptoms vary depending on whether the condition involves iron deficiency or overload. In iron deficiency diseases like iron-deficiency anemia (IDA), some of the common indications are fatigue, weakness, shortness of breath, pale skin, cold hands and feet, etc. Various other signs may include brittle nails, spoon-shaped nails, sore tongue (glossitis), etc. In contrast, iron overload disorders, such as hereditary hemochromatosis, can manifest with fatigue, joint pain, abdominal pain, changes in skin color (bronze or grayish hue), etc. Numerous additional symptoms may include liver enlargement (hepatomegaly), diabetes, heart abnormalities, impotence in men, etc. Diagnosing iron metabolism disorders involves a combination of medical history assessment, physical examination, laboratory procedures, and imaging studies. In suspected cases of iron-deficiency anemia, blood tests are used to measure hemoglobin, hematocrit, mean corpuscular volume (MCV), and serum ferritin levels. For iron overload disorders, transferrin saturation and liver function tests are performed to assess iron levels and organ damage.
The increasing prevalence of several chronic liver diseases, such as cirrhosis and hepatitis, which disrupt normal iron handling and lead to iron overload, is primarily driving the iron metabolism disorders market. In addition to this, the rising incidence of inherited blood diseases that result in abnormal hemoglobin production and high iron absorption is acting as another significant growth-inducing factor. Moreover, the widespread adoption of chelation therapy to reduce the iron burden in tissues and organs, thus minimizing the complications associated with iron overload, is further bolstering the market growth. Additionally, various key players are making extensive investments in R&D activities to introduce novel imaging agents, including superparamagnetic iron oxide nanoparticles (SPIONs), for more sensitive and specific detection of iron accumulation in tissues. This, in turn, is also creating a positive outlook for the market. Furthermore, the emerging popularity of longer-acting erythropoiesis-stimulating agent (ESA) formulations, since they maintain stable and sustained erythropoietic stimulation while allowing for less frequent dosing, is expected to drive the iron metabolism disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the iron metabolism disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for iron metabolism disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the iron metabolism disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the iron metabolism disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the iron metabolism disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current iron metabolism disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the iron metabolism disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the iron metabolism disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the iron metabolism disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of iron metabolism disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of iron metabolism disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of iron metabolism disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with iron metabolism disorders across the seven major markets?
What is the size of the iron metabolism disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of iron metabolism disorders?
What will be the growth rate of patients across the seven major markets?
Iron Metabolism Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for iron metabolism disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the iron metabolism disorders market?
What are the key regulatory events related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by status related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by phase related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by route of administration related to the iron metabolism disorders market?
The iron metabolism disorders market has been comprehensively analyzed in IMARC's new report titled "Iron Metabolism Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Iron metabolism disorders encompass a group of medical diseases characterized by abnormal levels of iron in the body. The symptoms vary depending on whether the condition involves iron deficiency or overload. In iron deficiency diseases like iron-deficiency anemia (IDA), some of the common indications are fatigue, weakness, shortness of breath, pale skin, cold hands and feet, etc. Various other signs may include brittle nails, spoon-shaped nails, sore tongue (glossitis), etc. In contrast, iron overload disorders, such as hereditary hemochromatosis, can manifest with fatigue, joint pain, abdominal pain, changes in skin color (bronze or grayish hue), etc. Numerous additional symptoms may include liver enlargement (hepatomegaly), diabetes, heart abnormalities, impotence in men, etc. Diagnosing iron metabolism disorders involves a combination of medical history assessment, physical examination, laboratory procedures, and imaging studies. In suspected cases of iron-deficiency anemia, blood tests are used to measure hemoglobin, hematocrit, mean corpuscular volume (MCV), and serum ferritin levels. For iron overload disorders, transferrin saturation and liver function tests are performed to assess iron levels and organ damage.
The increasing prevalence of several chronic liver diseases, such as cirrhosis and hepatitis, which disrupt normal iron handling and lead to iron overload, is primarily driving the iron metabolism disorders market. In addition to this, the rising incidence of inherited blood diseases that result in abnormal hemoglobin production and high iron absorption is acting as another significant growth-inducing factor. Moreover, the widespread adoption of chelation therapy to reduce the iron burden in tissues and organs, thus minimizing the complications associated with iron overload, is further bolstering the market growth. Additionally, various key players are making extensive investments in R&D activities to introduce novel imaging agents, including superparamagnetic iron oxide nanoparticles (SPIONs), for more sensitive and specific detection of iron accumulation in tissues. This, in turn, is also creating a positive outlook for the market. Furthermore, the emerging popularity of longer-acting erythropoiesis-stimulating agent (ESA) formulations, since they maintain stable and sustained erythropoietic stimulation while allowing for less frequent dosing, is expected to drive the iron metabolism disorders market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the iron metabolism disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for iron metabolism disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the iron metabolism disorders market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the iron metabolism disorders market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the iron metabolism disorders market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current iron metabolism disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the iron metabolism disorders market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the iron metabolism disorders market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the iron metabolism disorders market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of iron metabolism disorders across the seven major markets?
What is the number of prevalent cases (2018-2034) of iron metabolism disorders by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of iron metabolism disorders by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with iron metabolism disorders across the seven major markets?
What is the size of the iron metabolism disorders patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of iron metabolism disorders?
What will be the growth rate of patients across the seven major markets?
Iron Metabolism Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for iron metabolism disorders drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the iron metabolism disorders market?
What are the key regulatory events related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by status related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by phase related to the iron metabolism disorders market?
What is the structure of clinical trial landscape by route of administration related to the iron metabolism disorders market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IRON METABOLISM DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 IRON METABOLISM DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IRON METABOLISM DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 IRON METABOLISM DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IRON METABOLISM DISORDERS - UNMET NEEDS
10 IRON METABOLISM DISORDERS - KEY ENDPOINTS OF TREATMENT
11 IRON METABOLISM DISORDERS - MARKETED PRODUCTS
11.1 List of Iron Metabolism Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 IRON METABOLISM DISORDERS - PIPELINE DRUGS
12.1 List of Iron Metabolism Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. IRON METABOLISM DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. IRON METABOLISM DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 IRON METABOLISM DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Iron Metabolism Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Iron Metabolism Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Iron Metabolism Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Iron Metabolism Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Iron Metabolism Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Iron Metabolism Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Iron Metabolism Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Iron Metabolism Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Iron Metabolism Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Iron Metabolism Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Iron Metabolism Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Iron Metabolism Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Iron Metabolism Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Iron Metabolism Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Iron Metabolism Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Iron Metabolism Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Iron Metabolism Disorders - Access and Reimbursement Overview
16 IRON METABOLISM DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 IRON METABOLISM DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 IRON METABOLISM DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 IRON METABOLISM DISORDERS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 IRON METABOLISM DISORDERS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 IRON METABOLISM DISORDERS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 IRON METABOLISM DISORDERS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 IRON METABOLISM DISORDERS - UNMET NEEDS
10 IRON METABOLISM DISORDERS - KEY ENDPOINTS OF TREATMENT
11 IRON METABOLISM DISORDERS - MARKETED PRODUCTS
11.1 List of Iron Metabolism Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 IRON METABOLISM DISORDERS - PIPELINE DRUGS
12.1 List of Iron Metabolism Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. IRON METABOLISM DISORDERS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. IRON METABOLISM DISORDERS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 IRON METABOLISM DISORDERS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Iron Metabolism Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Iron Metabolism Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Iron Metabolism Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Iron Metabolism Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Iron Metabolism Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Iron Metabolism Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Iron Metabolism Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Iron Metabolism Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Iron Metabolism Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Iron Metabolism Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Iron Metabolism Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Iron Metabolism Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Iron Metabolism Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Iron Metabolism Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Iron Metabolism Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Iron Metabolism Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Iron Metabolism Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Iron Metabolism Disorders - Access and Reimbursement Overview
16 IRON METABOLISM DISORDERS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 IRON METABOLISM DISORDERS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 IRON METABOLISM DISORDERS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
